tbuckley/cabot-search huggingface dataset:
Determination of safingol, a sphingosine kinase inhibitor, in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry
Authors: Kyunghwa Hwang, Barry Maurer, C. Reynolds, Min Kang
Journal: Cancer Research (2007)

3961  Safingol, a saturated synthetic enantiomer of dihydrosphingosine, is a potential sphingosine kinase (SK) inhibitor that could decrease the formation of sphingosine-1 phosphaste (S1P) from degraded ceramide due to its stereoisomeric structure. Safingol has been reported to synergistically increase cytotoxicity of chemotherapeutic agents in tumor cell lines. An analytical method was developed for the quantitative determination of safingol in human plasma. Calibration curves were constructed in the range of 1-100 ng/ml, and were analyzed using a weight factor (1/x) proportional to the nominal concentration. Sample pretreatment involved a liquid-liquid extraction with ethyl acetate using 0.1 ml aliquots of plasma. The analyte was separated on a column (20mm × 2.1mm i.d.) packed with 3μm C18 material using a gradient elution with methanol (mobile phase B) and water containing 0.1% formic acid at a flow rate of 0.3 mL/min. The gradient profile was: hold at 60% mobile phase B for 0.5 min, linear gradient to 100% mobile phase B in 1 min, and hold at 100% mobile phase B for 1 min followed by 1 min re-equilibration. The mean retention time for safingol and C17 D-erythrosphinganine (internal standard) during the method validation was approximately 1.6 min and the overall chromatographic run time was established at 3 min. Detection was performed using a Q TRAPTM LC/MS/MS system by monitoring the ion transitions (MRM) from m/z 302.4 →59.9 (safingol) and m/z 288.3 →60.0 (C17 D-erythrosphinganine). Electrospray ionization was performed in the positive mode with an ionspray voltage of 5000eV. The other MS conditions were as follows: curtain gas, 25 psi; temperature 600 oC; ion source gas 1, 40 psi; ion source gas 2, 50 psi; CAD gas, medium; collision energy, 43 eV; declusting potential, 71 eV; entrance potential, 10 eV; collision cell exit potential 10 eV. The values for precision and accuracy were
Handling confounding variables in statistical shape analysis - application to cardiac remodelling
Authors: Gabriel Bernardino, Oualid Benkarim, María Sanz-de la Garza, Susanna Prat-Gonzàlez, Alvaro Sepulveda-Martinez, Fátima Crispi, Marta Sitges, Constantine Butakoff, Mathieu De Craene, Bart Bijnens, Miguel A. González Ballester
Journal: Medical Image Analysis (2020)
Machine Learning for Predicting Epileptic Seizures Using EEG Signals: A Review
Authors: Khansa Rasheed, Adnan Qayyum, Junaid Qadir, Shobi Sivathamboo, Patrick Kwan, Levin Kuhlmann, Terence O'Brien, Adeel Razi
Journal: IEEE Reviews in Biomedical Engineering (2020)

With the advancement in artificial intelligence (AI) and machine learning (ML) techniques, researchers are striving towards employing these techniques for advancing clinical practice. One of the key objectives in healthcare is the early detection and prediction of disease to timely provide preventive interventions. This is especially the case for epilepsy, which is characterized by recurrent and unpredictable seizures. Patients can be relieved from the adverse consequences of epileptic seizures if it could somehow be predicted in advance. Despite decades of research, seizure prediction remains an unsolved problem. This is likely to remain at least partly because of the inadequate amount of data to resolve the problem. There have been exciting new developments in ML-based algorithms that have the potential to deliver a paradigm shift in the early and accurate prediction of epileptic seizures. Here we provide a comprehensive review of state-of-the-art ML techniques in early prediction of seizures using EEG signals. We will identify the gaps, challenges, and pitfalls in the current research and recommend future directions.
Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From the Mother to the Infant—Reply
Authors: Lingkong Zeng, Tiantian Xiao, Wenhao Zhou
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
High Thrombus Burden in Patients With COVID-19 Presenting With ST-Segment Elevation Myocardial Infarction
Authors: Fizzah A. Choudry, Stephen M. Hamshere, Krishnaraj S. Rathod, Mohammed M. Akhtar, R. Andrew Archbold, Oliver P. Guttmann, Simon Woldman, Ajay K. Jain, Charles J. Knight, Andreas Baumbach, Anthony Mathur, Daniel A. Jones
Journal: Journal of the American College of Cardiology (2020)
Covid-19: an opportunity to reduce unnecessary healthcare
Authors: Ray Moynihan, Minna Johansson, Alies Maybee, Eddy Lang, France Légaré
Journal: BMJ (2020)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Covid-19: an opportunity to reduce unnecessary healthcare Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Estimation of Atherosclerotic Cardiovascular Disease Risk Among Patients in the Veterans Affairs Health Care System
Authors: Jason L. Vassy, Bing Lu, Yuk-Lam Ho, Ashley Galloway, Sridharan Raghavan, Jacqueline Honerlaw, Laura Tarko, John Russo, Saadia Qazi, Ariela R. Orkaby, Vidisha Tanukonda, Luc Djousse, J. Michael Gaziano, David R. Gagnon, Kelly Cho, Peter W. F. Wilson
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Current guidelines recommend statin therapy for millions of US residents for the primary prevention of atherosclerotic cardiovascular disease (ASCVD). It is unclear whether traditional prediction models that do not account for current widespread statin use are sufficient for risk assessment. <h3>Objectives</h3> To examine the performance of the Pooled Cohort Equations (PCE) for 5-year ASCVD risk estimation in a contemporary cohort and to test the hypothesis that inclusion of statin therapy improves model performance. <h3>Design, Setting, and Participants</h3> This cohort study included adult patients in the Veterans Affairs health care system without baseline ASCVD. Using national electronic health record data, 3 Cox proportional hazards models were developed to estimate 5-year ASCVD risk, as follows: the variables and published β coefficients from the PCE (model 1), the PCE variables with cohort-derived β coefficients (model 2), and model 2 plus baseline statin use (model 3). Data were collected from January 2002 to December 2012 and analyzed from June 2016 to March 2020. <h3>Exposures</h3> Traditional ASCVD risk factors from the PCE plus baseline statin use. <h3>Main Outcomes and Measures</h3> Incident ASCVD and ASCVD mortality. <h3>Results</h3> Of 1 672 336 patients in the cohort (mean [SD] baseline age 58.0 [13.8] years, 1 575 163 [94.2%] men, 1 383 993 [82.8%] white), 312 155 (18.7%) were receiving statin therapy at baseline. During 5 years of follow-up, 66 605 (4.0%) experienced an ASCVD event, and 31 878 (1.9%) experienced ASCVD death. Compared with the original PCE, the cohort-derived model did not improve model discrimination in any of the 4 age-sex strata but did improve model calibration. The PCE overestimated ASCVD risk compared with the cohort-derived model; 211 237 of 1 136 161 white men (18.6%), 29 634 of 218 463 black men (13.6%), 1741 of 44 399 white women (3.9%), and 836 of 16 034 black women (5.2%) would be potentially eligible for statin therapy under the PCE but not the cohort-derived model. When added to the cohort-derived model, baseline statin therapy was associated with a 7% (95% CI, 5%-9%) lower relative risk of ASCVD and a 25% (95% CI, 23%-28%) lower relative risk for ASCVD death. <h3>Conclusions and Relevance</h3> In this study, lower than expected rates of incident ASCVD events in a contemporary national cohort were observed. The PCE overestimated ASCVD risk, and more than 15% of patients would be potentially eligible for statin therapy based on the PCE but not on a cohort-derived model. In the statin era, health care professionals and systems should base ASCVD risk assessment on models calibrated to their patient populations.
SP0124 Pre-post operative care/joint replacement
Authors: L Mandrup Thomsen
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> The aim of surgical treatment of patients with rheumatic diseases is to provide pain relief and to improve the ability to function. The surgical offers of today are replacement of the joints, stiffening of the joints, synovectomia and various joint and tendon – correctioning operations. According to the shared care model the professional, contribution can be described as follows: Before the operation During the operation After the operation <b>Ad. 1. Before the operation</b> - Information about the operation (the operation and the weeks after the operation due to training, medicine, helping-aids and rehabilitation resuming work) - Physical training (specific and general training) - Regulation of medicine in collaboration with the rheumatologist - Occupational therapy (aids/splints) - Talking over the work situation of the patient before and after the operation - Diet and other lifestyle-habits (f.x. loss of weight, stop smoking) - Good advice while the patient is waiting for the operation <b>Ad. 2. The operation</b> Mentioning of the most frequent types of operations on people with rheumatic diseases. New types of operations to come. <b>Ad. 3. After the operation</b> - Painrelief - Rehabilitation - Temporary aids/splints - Resuming work, driving, leisure-time activities
Detection and Genetic Characterization of Community-Based SARS-CoV-2 Infections — New York City, March 2020
Authors: Dena Bushman, Karen A. Alroy, Sharon K. Greene, Page Keating, Amanda Wahnich, Don Weiss, Preeti Pathela, Christy Harrison, Jennifer Rakeman, Gayle Langley, Suxiang Tong, Ying Tao, Anna Uehara, Krista Queen, Clinton R. Paden, Wendy Szymczak, Erika P. Orner, Priya Nori, Phi A. Lai, Jessica L. Jacobson, Harjot K. Singh, David P. Calfee, Lars F. Westblade, Ljiljana V. Vasovic, Jacob H. Rand, Dakai Liu, Vishnu Singh, Janice Burns, Nishant Prasad, Jessica Sell
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

This report describes how the NYC Department of Health and Mental Hygiene conducted sentinel surveillance of influenza-like symptoms and genetic sequencing to characterize community transmission and determine the geographic origin of SARS-CoV-2 infections.
Abstract 14367: Diuretic Use is Associated With Worse Transplant-Free Survival in Adult Fontan Patients
Authors: Juan M Ortega-Legaspi, Katherine Awh, Bhavesh Patel, Abhinay Ramachandran, Joyce Wald, Srinivas Denduluri, Alexandra Archer, David Drajpuch, Stephanie Fuller, Christopher Mascio, Emily Ruckdeschel, Lynda Tobin, Yuli Y Kim
Journal: Circulation (2019)

Background: Single ventricle physiology can lead to heart failure necessitating diuretics, yet diuretic use and its prognostic value has not been fully explored in the adult Fontan patient. We aim ...
Gender Differences in Resident Assessment
Authors: Susan Hingle, Eileen Barrett
Journal: JAMA Network Open (2020)

Robin Klein, MD, MEHP; Nneka N. Ufere, MD; Sowmya R. Rao, PhD; Jennifer Koch, MD; Anna Volerman, MD; Erin D. Snyder, MD; Sarah Schaeffer, MD; Vanessa Thompson, MD; Ana Sofia Warner, MD, MBA; Katherine A. Julian, MD; Kerri Palamara, MD; for the Gender Equity in Medicine workgroup
Intranasal butorphanol rescue therapy for the treatment of intractable pruritus: A case series from the Johns Hopkins Itch Clinic
Authors: Raveena Khanna, Christina D. Kwon, Sagar P. Patel, Micah Belzberg, Kyle A. Williams, Ramona Khanna, Emily Boozalis, Shawn G. Kwatra
Journal: Journal of the American Academy of Dermatology (2020)
Delivery of a model lipophilic membrane cargo to bone marrow via cell-derived microparticles
Authors: Chunyan Yang, Fangfang Chen, Ping Ren, Laren Lofchy, Chun Wan, Jingshi Shen, Guankui Wang, Hanmant Gaikwad, Jessica Ponder, Craig T. Jordan, Robert Scheinman, Dmitri Simberg
Journal: Journal of Controlled Release (2020)
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India
Authors: Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, Akshat Pandey, Nikhil Gupta, Rahul Jain, Shashank Akerkar, Parthajit Das, Rajkiran Dudam, Naval Mendiratta, Bimlesh Dhar Pandey, Mithun CB, Bharat K Singh, Sharath Kumar, Nilesh Nolkha, Shriyanka Jain, Somya Jain, Ashish Sharma, Durga Prasanna Misra
Journal: Annals of the Rheumatic Diseases (2020)

We have read the recent report by Mathian et al with great interest where they described the clinical course of COVID-19 in 17 patients with systemic lupus erythematosus (SLE).1 The COVID-19 pandemic has caught the attention of the rheumatology fraternity due to a variety of reasons, such as the in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by hydroxychloroquine (HCQ),2 use of tocilizumab in the treatment of cytokine storm3 and concerns regarding cardiac toxicity due to HCQ.4 Patients with SLE are routinely prescribed HCQ and other immunosuppressants. The clinical picture of COVID-19 (such as pneumonia, cardiac injury, renal injury, venous thrombosis and septic shock) in patients with SLE on long-term HCQ described by Mathian et al intrigued the global rheumatology community.1 We assessed the impact of the pandemic on Indian patients with SLE in a larger multicentric survey. We expected that differences in disease expression, ethnicity and treatment may possibly alter the impact of the pandemic in contrast to the aforementioned study. We included patients who had visited their …
Covid-19: What we eat matters all the more now
Authors: Fiona Godlee
Journal: BMJ (2020)

Concern about a winter wave of covid-19 is rightly prompting calls for intense preparation.Measures to minimise community transmission and strengthen the test, trace, and isolate programme must start now, says the Academy of Medical Sciences, if we are to avoid double the number of hospital deaths seen in this first wave. 1 The NHS also faces a huge workload in delayed treatment for people with cancer and support for people struggling with "long covid." 2 3 These mounting problems further justify calls for a rapid review of the UK's preparedness.
AB1113 DIAGNOSTIC VALUE OF ANTI-Sa AND ANTI-hn RNP K ANTIBODIES IN SERONEGATIVE RHEUMATOID ARTHRITIS
Authors: M. Volkava, A. Kundzer
Journal: Annals of the Rheumatic Diseases (2020)

Background: The diagnostics of seronegative rheumatoid arthritis (RA) remains the important issue in modern rheumatology. Other biomarkers are studied to close the diagnostic gap. Objectives: The aim of work was to assess anti-Sa and anti-hnRNP K in patients with RA and to evaluate their diagnostic value in seronegative by anti-CCP and RF RA. Methods: In the study were included 270 patients, which fulfill EULAR/ACR 2010 criteria for RA and 50 healthy controls. The mean of patients age was 52.80 (95% CI:51.70-54.80 years). Levels of antibodies to anti-CCP and anti-Sa were evaluated by ELISA according to the instructions of the manufacturer (Euroimmune, Germany), anti-hnRNP K according to the instructions of the manufacturer ((Medipan, Germany). Levels of rheumatoid factor (RF) were assessed by kinetic nephelometry using an automatic analyzer Beckman Coulter (USA). Results: Anti-CCP in patients were found 209 (77.41%) patients, RF - in 192 (71.11%) patients, anti-Sa – in 163 (60.37%) patients, anti-hnRNP K – in 63 (23.33%) patients. The incidence of Anti-CCP, RF, anti-Sa, anti-hnRNP K in RA was significantly higher (p&lt;0.05) than in healthy individuals (0 (0%), 0 (0%), 1 (2.00%), 0 (0%) respectively). The diagnostic sensitivity and specificity of anti-Sa to discriminate seronegative by anti-CCP and RF RA patients from healthy controls by ROC – analysis were determined and made up for anti-Sa - 50,00% (95%CI: 26.1 – 73.9) and 96.77% (95%CI: 83.2 – 99.5) respectively (area under ROC-curve 0.734; 95%CI: 0.588-0.850, p=0.0026), for anti-hnRNP K - 55,56% (95%CI:35,3 - 74,5), 100,00% (95%CI: 95,7 - 100,0) respectively (area under ROC-curve 0.778; 95%CI: 0.689-0.851, p=0.0001). There were no significant differences in clinical (DAS 28, CDAI, SDAI, treatment options) and laboratory characteristics (ESR, CRP, anti-CCP, RF levels) between anti-Sa-positive and anti-Sa-negative patients (p&gt;0.05) as well as between anti-hnRNP K-positive and anti-hnRNP K-negative patients (p&gt;0.05). Conclusion: Anti-Sa and anti-hnRNP K may serve as potential additional laboratory biomarkers for seronegative RA to allow to close the seronegative RA gap and confirm the diagnosis of RA. Disclosure of Interests: None declared
Evidencing a Pancreatic Ductal Adenocarcinoma Subpopulation Sensitive to the Proteasome Inhibitor Carfilzomib
Authors: Nicolas A. Fraunhoffer, Analía Meilerman Abuelafia, Martin Bigonnet, Odile Gayet, Julie Roques, Emmanuel Telle, Patricia Santofimia-Castaño, María Teresa Borrello, Eduardo Chuluyan, Nelson Dusetti, Juan Iovanna
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient prognosis; however, the clinical efficacy of these treatments is low. One of the most controversial family of drugs are the proteasome inhibitors, which have displayed promising effects in preclinical studies, but low clinical performance. Here, we unravel a specific transcriptomic signature that discriminates a subgroup of patients sensitive to the proteasome inhibitor carfilzomib. Experimental Design: First, we identified a subpopulation of PDAC-derived primary cells cultures (PDPCC) sensitive to the proteasome inhibitor carfilzomib. Then, we selected a transcriptomic signature that predicts carfilzomib chemosensitivity using independent component analysis on the transcriptome of PDPCC. Finally, we validated the signature in an independent cohort of PDAC biopsy-derived pancreatic organoids. Results: Sensitive phenotype was characterized by a high expression of genes related with a cornified/squamous pathway and a downregulation of epithelial–mesenchymal transition genes. Interestingly, carfilzomib-sensitive transcriptomic profile did not show any association with the proteasome activity but strongly correlates with ATF4 and CHOP expression, which are key markers of the unfolded protein response and critical to trigger the cell death program. Concordantly, sensitive phenotype showed a high level of the de novo RNA and protein synthesis compared with the resistant one and, most important, cell death induced by carfilzomib is dependent of the translational activity. Conclusions: We demonstrate the existence of a carfilzomib-sensitive PDAC subgroup with a specific transcriptomic phenotype that could explain the biological reason for this responsiveness.
The APRIN gene (AS3) is downregulated in invasive breast cancers
Authors: Peter Geck, Maricel Maffini, Shu Ling Liang
Journal: Cancer Research (2004)

5595  B ac k g r o u n d. The APRIN gene was first isolated from prostate cancer cells. It was shown to be upregulated in androgen-induced proliferative arrest and microsatellite markers detected its genomic loss in a number of prostate and other cancers. We mapped the gene on chromosome 13q12.3, in close proximity to BRCA2, a breast cancer associated gene. In most sporadic breast cancers BRCA2 is intact, but deletions indicated a cryptic breast cancer suppressor gene next to BRCA2, in the APRIN area. O b j e c t i v e. The aim of our study was to investigate if these deletions targeted the APRIN gene and whether the loss of APRIN expression correlates with breast cancer, indicating a critical role for APRIN. M e t h o d. We generated an affinity purified polyclonal anti-APRIN antibody and we used immunoblots and immunohistochemistry to detect APRIN expression and localization in normal and breast cancer cells. We developed a tetracycline regulated APRIN expression system to investigate its effect on proliferation. We analyzed in silico microarray and SAGE data to examine APRIN expression in various breast cancer cell lines and breast cancer samples; and we analyzed 57 invasive ductal breast adenocarcinomas to assess APRIN expression. R e s u l t s. Western analysis detected APRIN expression in human breast epithelial cells, in the MCF7 cell line. Immunohistochemistry in normal human breast tissue sections showed that it was predominantly nuclear and mostly epithelial. The tetracycline-induced APRIN expression system in breast cancer cells showed that APRIN induction arrested the proliferation of mammary gland epithelial cells. The in silico microarray and SAGE data indicated that APRIN expression was absent in most of the breast cancer cell lines and clinical cancer samples. Our immunohistochemical analysis detected high expression of APRIN in normal breast tissues. In contrast, our analysis of 57 clinical breast cancer samples indicated that in 90 % of the invasive ductal breast adenocarcinomas APRIN was absent or downregulated. C o n c l u s i o n s. Our results strongly suggest that APRIN is not primarily androgen regulated, its function is not exclusively prostate specific and it also has a critical role in breast cancer. The APRIN protein has domains typical of chromatin regulators and it may link hormonal regulation to chromatin in differentiation and cancer.